Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmaceutical industry economics

The number of microencapsulated commercial oral formulations available and the volume of these formulations sold annuaUy is comparatively smaU. This may reflect the difficulty of developing new dmg formulations and bringing them successfully to market or the fact that existing microencapsulation techniques have had difficulty economically producing mictocapsules that meet the strict performance requirements of the pharmaceutical industry. One appHcation that is a particularly active area of development is mictocapsules or microspheres for oral deUvery of vaccines (45,46). [Pg.324]

There are many reasons for carrying out the laboratory synthesis of an organic compound. In the pharmaceutical industry, new organic molecules are designed and synthesized in the hope that some might be useful new drugs. In the chemical industry, syntheses are done to devise more economical routes to known compounds. In academic laboratories, the synthesis of complex molecules is... [Pg.274]

In a catalytic asymmetric reaction, a small amount of an enantio-merically pure catalyst, either an enzyme or a synthetic, soluble transition metal complex, is used to produce large quantities of an optically active compound from a precursor that may be chiral or achiral. In recent years, synthetic chemists have developed numerous catalytic asymmetric reaction processes that transform prochiral substrates into chiral products with impressive margins of enantio-selectivity, feats that were once the exclusive domain of enzymes.56 These developments have had an enormous impact on academic and industrial organic synthesis. In the pharmaceutical industry, where there is a great emphasis on the production of enantiomeri-cally pure compounds, effective catalytic asymmetric reactions are particularly valuable because one molecule of an enantiomerically pure catalyst can, in principle, direct the stereoselective formation of millions of chiral product molecules. Such reactions are thus highly productive and economical, and, when applicable, they make the wasteful practice of racemate resolution obsolete. [Pg.344]

Comprehensive physicochemical characterization of any raw material is a crucial and multi-phased requirement for the selection and validation of that matter as a constituent of a product or part of the product development process (Morris et al., 1998). Such demand is especially important in the pharmaceutical industry because of the presence of several compounds assembled in a formulation, such as active substances and excipients, which highlights the importance of compatibility among them. Besides, variations in raw materials due to different sources, periods of extraction and various environmental factors may lead to failures in production and/or in the dosage form performance (Morris et al., 1998). Additionally, economic issues are also related to the need for investigating the physicochemical characteristics of raw materials since those features may determine the most adequate and low-cost material for specific procedures and dosage forms. [Pg.65]

Catalysts are extensively used and have played a huge role in making bulk chemical manufacturing technology more competitive and environmentally fnendly. Undoubtedly catalysis will continue to provide the answer to many economic and environmental challenges currently faced by industry. As indicated above catalysts are now needed by the fine chemical and pharmaceutical industries, and they need to be robust, selective, recoverable and reusable. [Pg.128]

Vanillin (4-hydroxy-3-methoxybenzaldehyde) is widely used in foods, beverages, perfumes and the pharmaceuticals industries. Biotransformation of isoeugenol from essential oil to vanillin represents an economic route for the supply of vanillin, which has a limited supply due to the availability of vanilli pod plants. The conversion yield of isoeugenol to vanillin by the whole-cell biotransformation process of Bacillus fusiformis was low due to the product inhibition effect. Adding resin HD-8 to the whole-cell biotransformation eliminated the product inhibition effect, yielding 8 gL 1 of vanillin in the final reaction mixture [27]. The resin HD-8 also facilitated the separation of vanillin from the used substrate. The recovered isoeugenol can be used for the subsequent biotransformation reaction. [Pg.236]

Abbott III, T.A. (1994), Price regulation in the pharmaceutical industry prescription or placebo , Journal of Health Economics, 14, pp. 551-65. [Pg.57]

Scherer, F.M. (1993), Pricing, profits, and technological progress in the pharmaceutical industry , Journal of Economic Perspectives, 1 (3), 97-115. [Pg.58]

The innovative pharmaceutical industry is one of the clearest exponents of the familiar process of the globalization of the economy. The reasons for this are obvious first, companies need to recover the huge investment in R D that is necessary to get an innovative medicinal product with added therapeutic value onto the market. Second, the cost of transporting pharmaceuticals is usually low in comparison with the economic value of the product, which facilitates the geographical extension of markets. Finally, the company does not even need to transport goods, as it can limit itself to selling technology, especially if the innovation is protected by a system of patents, and this facilitates international expansion even more. [Pg.91]

Caves, R.E., M.D. Whinston and M.A. Hurwitz (1991), Patent expiration, entry, and competition in the US pharmaceutical industry , Brooking Papers on Economic Activity, 1991, 1-66. [Pg.123]

Review of economic studies of the pharmaceutical industry published over the last 20 years by Spanish economists... [Pg.210]

We could say that in Spain today there is an invisible college uniting Spanish researchers interested in the economics of pharmaceuticals and the pharmaceutical industry. This can be seen by analysing the cross-references. It is also symptomatic that practically every year a special session dedicated to this topic is held at the Conference on Health Economics. [Pg.211]

Most of the works we mention below share a common interest in the economic causes and effects of the regulation of the pharmaceutical industry and drags. That is, they are concerned about analysing the role of the state when it intervenes in the market. [Pg.213]

Mestre, J. (1999), The impact of generic goods in the pharmaceutical industry , Health Economics, 8, 599-612. [Pg.233]


See other pages where Pharmaceutical industry economics is mentioned: [Pg.644]    [Pg.223]    [Pg.460]    [Pg.644]    [Pg.340]    [Pg.221]    [Pg.286]    [Pg.287]    [Pg.354]    [Pg.34]    [Pg.429]    [Pg.24]    [Pg.319]    [Pg.320]    [Pg.73]    [Pg.77]    [Pg.445]    [Pg.453]    [Pg.3]    [Pg.233]    [Pg.297]    [Pg.177]    [Pg.34]    [Pg.57]    [Pg.135]    [Pg.148]    [Pg.179]    [Pg.182]    [Pg.211]    [Pg.214]    [Pg.215]    [Pg.156]   


SEARCH



Industrial economics

Pharmaceutical industry

Pharmaceutical industry economic factors

Pharmaceutical industry, economic pressure

© 2024 chempedia.info